Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

• Published in: Diabetes, obesity & metabolism Vol. 20; no. 2; pp. 409 - 418
• Main Authors: Gallwitz, Baptist, Dagogo‐Jack, Samuel, Thieu, Vivian, Garcia‐Perez, Luis‐Emilio, Pavo, Imre, Yu, Maria, Robertson, Kenneth E., Zhang, Nan, Giorgino, Francesco
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.02.2018; Wiley Subscription Services, Inc
• Subjects: Aged; Blood Glucose - analysis; Body weight; Body weight loss; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diarrhea - chemically induced; Drug Administration Schedule; Drug Therapy, Combination - adverse effects; dulaglutide; Fasting; Female; Gender; GLP‐1; GLP‐1 analogue; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor - agonists; Glucagon-Like Peptide-1 Receptor - metabolism; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - analogs & derivatives; Glucagon-Like Peptides - therapeutic use; Glucose; Glycated Hemoglobin A - analysis; Hemoglobin; Humans; Hyperglycemia - prevention & control; Hypoglycemia; Hypoglycemia - chemically induced; Hypoglycemia - prevention & control; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Immunoglobulin Fc Fragments - administration & dosage; Immunoglobulin Fc Fragments - adverse effects; Immunoglobulin Fc Fragments - therapeutic use; Insulin; Insulin - administration & dosage; Insulin - adverse effects; Insulin - therapeutic use; Laboratory testing; Male; Middle Aged; Nausea - chemically induced; Original; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - therapeutic use; Sex Characteristics; Subpopulations; type 2 diabetes; Vomiting - chemically induced; Weight Gain - drug effects; Weight Loss - drug effects; GLP-1; type 2 diabetes; dulaglutide; GLP-1 analogue

Aims To evaluate the efficacy and safety of dulaglutide 1.5 and 0.75 mg in patients with type 2 diabetes by subgroups of gender, duration of diabetes and baseline glycated haemoglobin (HbA1c) in the dulaglutide clinical development programme (AWARD‐1 to ‐6 and ‐8 clinical trials). Methods Change in...